Issue of Equity and Total Voting Rights

Avacta Group PLC

13 May 2026

 

Avacta Group plc

("Avacta", the "Group" or the "Company")

Issue of Equity and Total Voting Rights 

LONDON and PHILADELPHIA - May 13, 2026 - Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION^®, a tumor-activated oncology delivery platform, today announces it has issued and allotted a total 1,604,063 new ordinary shares of 10 pence each in the Company ("New Ordinary Shares").

The New Ordinary Shares are being issued in settlement of a Notice of Conversion for £1.20 million of the principal amount of the Company's unsecured convertible bond (the "Conversion").

As a result of the Conversion, the principal remaining under the convertible bond will be reduced by £1.20 million to £19.20 million.  

Admission and Total Voting Rights

Application has been made to AIM for the admission to trading of the 1,604,063 New Ordinary Shares to trading on AIM ("Admission"). It is expected Admission will become effective and dealings in such Ordinary Shares will commence at 8.00 am on or around 18 May 2026. The New Ordinary Shares will rank pari passu in all respects with the existing Ordinary Shares of the Company. 

Immediately following Admission, the Company's enlarged issued share capital will be 457,892,574 Ordinary Shares. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. 

-Ends-

For further information from Avacta, please contact:

Avacta Group plc Christina Coughlin, Chief Executive Officer	https://avacta.com/ via Cohesion Bureau
Strand Hanson Limited (Nominated Adviser) James Harris / Chris Raggett / James Dance	www.strandhanson.co.uk
Zeus (Broker) James Hornigold / George Duxberry / Dominic King	www.zeuscapital.co.uk
Cohesion Bureau Communications / Media / Investors Richard Jarvis	[e-mail]

About Avacta - https://avacta.com/

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies through its proprietary pre|CISION® platform. pre|CISION® is a payload delivery system based on a tumor-specific protease (Fibroblast Activation Protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Avacta's innovative pre|CISION® peptide drug conjugates (PDC) are a novel entry to the XDC drug class, leveraging the success of antibody drug conjugates with alternative methods of delivery beyond antibodies. 

Our pre|CISION® PDCs leverage this tumor-specific release mechanism to provide unique benefits over traditional antibody drug conjugates, releasing active payload in the tumor and reducing systemic exposure and toxicity which enables dosing to be optimized to deliver the best outcomes for patients. The lead clinical program is faridoxorubicin (AVA6000), a Gen One FAP-enabled pre|CISION® version of doxorubicin that delivers the payload directly in the tumor with limited peripheral blood exposure and has demonstrated preliminary activity in tumor types sensitive to doxorubicin including salivary gland cancer and soft tissue sarcoma. 

About AVA6103 (FAP-Exd)

AVA6103 is the second clinical candidate and is based on the innovative pre|CISION^® sustained release mechanism that provides for prolonged release of payload directly in the tumor, minimizing systemic exposure.  AVA6103 is being evaluated in the FOCUS-01 Phase 1 trial (FAP-Exd in Oncologic Cancers with Unmet needS). Preclinical data suggest this approach has optimized payload delivery with a high intratumoral concentration and prolonged exposure of released payload in the tumor, coupled with limited systemic exposure to the released payload. 

 

END